Adoptive T-cell therapy – the “Advance of the Year” – offered at Providence in clinical trials for lymphoma, melanoma, lung, head and neck cancers

June 28, 2018

Providence Cancer Institute is one of the few specialized centers in the world offering clinical trials of adoptive T-cell immunotherapy, a treatment approach so promising that the American Society of Clinical Oncology (ASCO) named it the 2018 Advance of the Year.

Two especially encouraging approaches have become major research priorities for the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center:

  • TIL therapy: This therapy focuses on multiplying the patient’s cancer-fighting T-cells. TILs (the cancer-fighting T-cells known as tumor-infiltrating lymphocytes) are extracted from the patient’s tumor, multiplied by billions in a lab, and returned to the patient.
  • CAR T-cell therapy: This treatment focuses on making the T-cells smarter. The patient’s T-cells are manipulated in a lab to express proteins called chimeric antigen receptors (CARs), which help the T-cells recognize tumor cells. These engineered CAR T-cells are then multiplied and given back to the patient.

Providence is the first cancer center in Oregon, and one of only a handful in the country, to offer these therapies in clinical trials. Currently, several trials are open for people with a variety of cancers, including these:

For more information or to enroll a patient, call our Clinical Research office at 503-215-2614.

Find out more about adoptive T-cell therapy research at Providence.

See more studies

New research studies are added frequently. Please visit our website to see all studies in all cancer types currently open at Providence Cancer Institute.